providing special products to special people

• Home
• About Us
  • Corporate Strategy
  • Organization
  • Management
    • Experience
  • Supervisory Board
  • Investors
• Products
  • Dantrium^® / Dantrolen^®
  • Savene^®
  • MuGard™
  • Xerotin^®
  • PROTHER™
• Business Development
  • Partnerships
• Careers
• Press Room
• Contacts
• Legal Disclaimer

• 01/09/2011

  Sale of Japanese Rights for Savene to Kissei Pharmaceuticals

• 31/05/2011

  The Paris Court of Appeals rejects the appeals lodged by BioAlliance Pharma in a case against Spepharm Holding B.V. and

• 10/10/2010

  European clinical experience with MuGard presented at ESMO 2010 Congress

Information on
Dantrium / Dantrolen »
Informationen zu
Dantrium / Dantrolen »
Informaciones sobre
Dantrium / Dantrolen »
A propos du
Dantrium / Dantrolène »
Informazioni su
Dantrium / Dantrolen »

Lokaler Ansprechpartner in Deutschland:

SpePharm GmbH
info.deutschland@spepharm.com

Ausführliche deutschsprachige Informationen zu Dantrolen i.v. unter www.dantrolen.de